BAM-15 30mg/mL 30mL

BAM-15 is a mitochondrial proton uncoupler — it dissipates the proton gradient across the inner mitochondrial membrane that normally drives ATP synthesis, converting that stored electrochemical energy into heat rather than ATP production. This uncoupling mechanism increases energy expenditure (metabolic rate elevation) without the cardiovascular toxicity, hyperthermia risk, or thyroid-like adverse effects that have prevented older uncouplers from clinical development. BAM-15 is the most selectively tolerated mitochondrial uncoupler ever pharmacologically characterized.

The energy coupling mechanism of the mitochondria works as follows: electron transport chain (ETC) activity pumps protons from the mitochondrial matrix to the intermembrane space, creating an electrochemical gradient (proton-motive force) that drives ATP synthesis through the F1F0-ATP synthase. Chemical uncouplers allow protons to flow back across the inner mitochondrial membrane directly, bypassing ATP synthase — dissipating the proton-motive force as heat rather than ATP. The metabolic consequence is that ETC activity must increase to maintain mitochondrial function, dramatically increasing substrate (glucose, fatty acids) oxidation rate without producing proportional ATP. The cell burns more fuel to maintain the same energy currency.

The classical uncoupler DNP (2,4-dinitrophenol) operates through this mechanism and produces powerful fat loss — but caused multiple human deaths from uncontrolled hyperthermia when used by bodybuilders, as systemic uncoupling at therapeutic doses produced dangerous heat generation. BAM-15's selectivity advantage is its preferential accumulation in mitochondria with higher membrane potential (more depolarized) — meaning it concentrates preferentially in metabolically active tissues like brown adipose tissue, liver, and muscle rather than distributing uniformly to all tissues including the heart. This selective accumulation profile, combined with its molecular structure that limits passage across plasma membranes, restricts uncoupling activity to metabolic tissues and substantially reduces systemic thermogenic risk.

Preclinical data in murine obesity models demonstrates BAM-15's metabolic effects: significant fat mass reduction, improved insulin sensitivity, and metabolic rate elevation without the temperature increases or cardiovascular effects observed with non-selective uncouplers. In diet-induced obese mice, BAM-15 produced fat loss comparable to semaglutide with improved metabolic markers — particularly reduced lipid peroxidation and oxidative stress markers (ROS reduction is a counter-intuitive benefit of uncoupling, as reduced proton gradient backpressure decreases superoxide production at complex I/III). The reduction in mitochondrial ROS production with BAM-15 has made it a subject of interest in metabolic disease contexts beyond just fat loss — including insulin resistance, fatty liver, and neurodegeneration models where mitochondrial oxidative stress is a driving pathology.

The 30mg/L (30mL) formulation provides 0.9mg total BAM-15 in injectable liquid form — a precise low-concentration format suitable for research dosing protocols where exact dose titration is required. BAM-15 remains a research compound without human clinical data.